First AD

Second AD

Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

Video content above is prompted by the following:

Please discuss the NCCN guideline recommended first-line treatment options for patients with newly diagnosed high-risk or secondary AML who are potential candidates for intensive chemotherapy induction.

Please briefly review the study design & efficacy study of CPX-351 vs. 7+3.

How do you monitor and manage potential adverse effects in these patients?

Describe management of both 7+3 and CPX-351.

How does your approach differ between the two regimens?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Optimizing Intensive Chemotherapy Management in Secondary AML Through Academic Community Collaboration 

Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.